Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FXRW4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,154
Award facts
- Contract value 100% obligated
- $16,154.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on September 26, 2025, for Stelara 90 mg/mL syringes with a ceiling value of $16,154.36. This firm fixed-price delivery order represents a continuation of the company's substantial work under the DLA's SPE2DB program, a $500 million indefinite delivery contract that serves as the primary vehicle for pharmaceutical supply to Department of Defense healthcare facilities. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete directly in the open federal market despite its small business status. The delivery order is scheduled for ultimate completion by October 20, 2025, with performance taking place at the company's Park Ridge, Illinois location.
Stelara is a biologic immunosuppressant medication used to treat autoimmune conditions, and this delivery order fulfills an acute supply need for military medical facilities. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its extensive portfolio of branded and generic pharmaceuticals, biologics, and medical consumables. The company's consistent success in securing contracts with the DLA—without relying on set-aside programs—demonstrates its competitive capability in federal procurement and its essential role in ensuring pharmaceutical availability across the Department of Defense healthcare system.
Quick answers
Who was awarded contract SPE2DB25FXRW4?
SPE2DB25FXRW4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 26, 2025.
How much is contract SPE2DB25FXRW4 worth?
The government has obligated $16,154 on SPE2DB25FXRW4.
Is contract SPE2DB25FXRW4 an order under another contract?
Yes. SPE2DB25FXRW4 is a delivery order under SPE2DB24D9131, an indefinite delivery contract.
Was contract SPE2DB25FXRW4 competed?
The extent of competition for SPE2DB25FXRW4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award